Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies

Stefano Stano,[1] Fabio Cacciapaglia,[1,2] Laura Coladonato,[1] Giuseppe Lopalco,[1] Florenzo Iannone,[1] Marco Fornaro[1]

[1]Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari;
[2]Department of Medicine and Surgery, LUM 'G. De Gennaro', Casamassima, Italy

Correspondence: Marco Fornaro, Unit of Rheumatology, Department of Precision and Regenerative Medicine and Ionian Area, Piazza G Cesare, 11 70124 Bari, Italy.
E-mail: marco.fornaro@uniba.it

Key words: myositis, rituximab, safety, effectiveness.

Summary

Objective. Idiopathic inflammatory myopathies (IIM) are heterogeneous autoimmune diseases including dermatomyositis (DM), polymyositis (PM), immune-mediated necrotizing myopathy (IMNM), and anti-synthetase syndrome (ASS). Treatment typically involves high-dose corticosteroids (CCS) and conventional synthetic disease-modifying antirheumatic drugs (csDMARD). Rituximab (RTX) has shown effectiveness in refractory cases. Our real-life study aimed to assess the safety and effectiveness of RTX treatment in IIM patients.

Methods. We conducted a retrospective study including patients with IIM refractory to both high-dose CCS and csDMARD. Patients were treated with a full RTX dose (2 g every 6 months). Laboratory and clinical data, along with the total improvement score (TIS), were assessed to evaluate RTX effectiveness and safety. Data were analyzed using GraphPad Prism (v. 9.5.1).

Results. A total of 41 patients received the full RTX dose (15 DM, 15 ASS, 5 PM, and 6 IMNM). This treatment regimen significantly reduced daily CCS usage from 15 mg [interquartile range (IQR) 12.5-25 mg] at baseline to 5 mg (IQR 5-5 mg) after 1 year of treatment ($p<0.001$). Additionally, over 90% of patients achieved at least a minimal TIS at 12 months, which was maintained at 24 months. At 1 year, RTX persistence was 68.3%. Although reductions in serum immunoglobulins (Ig)A and IgM levels were observed, no cases of severe hypogammaglobulinemia (IgG<400 mg/dL) occurred. The most common reason for treatment interruption was an adverse skin reaction (6 cases) during RTX infusion, while infections most frequently involved the respiratory tract (5 cases).

Conclusions. RTX demonstrated effectiveness in various subsets of IIMs, often leading to clinical improvement and significantly reducing the CCS dose.

Introduction

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune systemic diseases with variable clinical manifestations, treatment responses and prognoses. Muscle weakness, reduced muscle endurance, and myalgia are the most classical clinical manifestations, but many organs may be affected, sometimes representing the predominant manifestation of the disease. Extra-muscular manifestations of IIM are relatively common and include different skin manifestations, articular involvement as arthritis or arthralgia, lung involvement, most commonly as interstitial lung disease (ILD), gastrointestinal manifestations, and heart involvement, which may be potentially fatal (1). Among the different gastrointestinal manifestations, esophageal involvement with dysphagia represents a frequently disabling and early symptom of dermatomyositis (DM), reported by 20-50% of patients (2). Due to the rare and heterogeneous nature of IIM and the small number of studies carried out, there is a lack of consensus on the use of the available therapeutic options. Therefore, the choice is often empirical and not based on shared therapeutic algorithms (3-5). According to general clinical consensus, treatment of IIM involves the use of high-dose corticosteroids (CCS) as the first-line drug to induce remission and conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs), including azathioprine, mycophenolate mofetil, calcineurin inhibitors, cyclophosphamide, and methotrexate, as steroid-sparing agents to maintain the remission state (6). Unfortunately, many patients are refractory to CCS and immunosuppressive agents; therefore, alternative strategies, including immunomodulators such as intravenous immunoglobulins (Ig), and biologic (b) DMARDs, have been employed with variable success (7). The rationale for using bDMARDs in IIM resides in their ability to interfere with the immune-mediated activation of selected inflammatory pathways, avoiding the broader immunosuppressive effect induced by csDMARDs. The growing knowledge about the complex pathophysiology of IIM strongly supports the implementation of bDMARDs, including rituximab (RTX), tocilizumab, tumor necrosis factor α inhibitors, and abatacept, in specific treatment guidelines (8). RTX is a chimeric monoclonal antibody binding the CD20 antigen expressed on the surface of B lymphocytes at most stages of their development, but not on pro-B cells, early pre-B cells, and plasma cells, causing rapid depletion of CD20-positive B lymphocytes from the peripheral blood for up to 6-9 months. Despite the beneficial effects of RTX in IIM being suggested by case reports and case series, the experience in patients with refractory disease is limited, and current evi-

dence supports the off-label use of RTX in patients with refractory IIM (9). The Rituximab in Myositis (RIM) study was the largest randomized, double-blind, placebo-controlled trial comparing early *vs.* late treatment with RTX to achieve clinical improvement and included 195 IIM patients refractory to CCS and at least one immunosuppressive agent. Although the time to achieve the primary endpoint was not different between the two RTX treatments, many patients (83%) with refractory disease experienced clinical improvement and a steroid-sparing effect. Additionally, the treatment was generally well tolerated, with infections being the most common adverse event (10). In our study, we aimed to evaluate the safety and effectiveness of RTX treatment in patients with various subsets of IIM in a real-world setting.

Materials and Methods

Population

Patients with IIM refractory to conventional therapy with high-dose CCS and csDMARDs and deemed suitable for RTX therapy based on clinician judgment were included in our retrospective study. The refractoriness to conventional therapy was defined as therapy ineffectiveness, with lack of improvement or worsening of clinical manifestations, according to both clinician assessment and patient subjective evaluation, after at least 3 to 6 months of continuous treatment, or therapy interruption due to any adverse reaction of csDMARDs, or inability to reduce daily CCS dose below 5mg prednisone (PDN) equivalent (PDNeq). Patients affected by DM or polymyositis (PM) were defined according to the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology classification criteria. Patients with antisynthetase syndrome (ASS) were defined by the presence of ASS antibodies and at least one clinical manifestation, including arthritis, ILD or myositis, while patients with immune mediated necrotizing myopathy (IMNM) were defined by the presence of anti-SRP or anti-HMGCR antibodies or by histological features of necrotizing myopathy in the absence of autoantibodies (11, 12). All patients included in this study were treated with RTX, administered as two 1g infusions given 2 weeks apart every 6 months. For each patient, refractory disease manifestations requiring RTX prescription were reported, including skin, muscle, joint, and lung involvements. The persistence of RTX therapy was defined by the clinical decision, shared with the patient, to continue RTX treatment after 1 year from the first infusion. Patients in remission were defined according to clinician judgment, with physician global assessment and extra-muscular disease activity visual analog scales at 0. Prior to each RTX infusion, patients were appropriately premedicated with methylprednisolone 100 mg intravenously, antihistamines, acetaminophen, and proton pump inhibitors, according to the RTX medication administration protocol. Demographic, clinical, and laboratory data of enrolled IIM patients were evaluated at baseline and during follow-up. Lung involvement was defined as ILD confirmed by a lung high-resolution computed tomography scan. Laboratory data included: creatine phosphokinase (CPK), anti-nuclear antibodies, myositis-specific autoantibodies (MSA), and myositis-associated autoantibodies (MAA) (Euroline Autoimmune Inflammatory Myopathies, Euroimmun, Germany, or MYO12D-24, D-Tek, Belgium). Ongoing and previous treatments were recorded, including CCS (with their dosages) and immunosuppressive agents. Serum Ig levels were monitored and recorded at baseline, 1 year, and 2 years. Significant hypogammaglobulinemia was defined as a serum IgG level below 400 mg/dL (13). Reasons for RTX treatment interruption and adverse drug reactions (ADRs) causing RTX discontinuation up to 1 year after the last administration were recorded during follow-up. According to clinical charts, primary ineffectiveness was defined as the patient stopping RTX within the first year of treatment, while secondary failure was defined as the clinical decision to stop RTX after more than 1 year of treatment. Treatment effectiveness was evaluated by the total improvement score (TIS), calculated at 1 year and at 2 years since RTX initiation. This score, calculated using the International Myositis Assessment and Clinical Studies Group calculator, classifies clinical improvement as minor, moderate, major, or no clinical improvement according to the myositis response criteria. Furthermore, treatment outcome was assessed with appropriate clinical and instrumental exams, monitored at first RTX infusion, 1-year, and 2-year follow-up visits. Specifically, in IIM patients with refractory muscle involvement, the manual muscle test (MMT) in eight muscular districts bilaterally (MMT-8, score 0-150) and CPK level were monitored, while IIM patients with refractory lung involvement were monitored by forced vital capacity (FVC) and diffusion lung carbon monoxide (DLCO) predicted values (%). All participants signed an informed consent prior to inclusion in the study, which was approved by the local Ethics Committee (INflammatoy MYositis Registry: study no. 6229, approval no. 84762,2020/11/06; comitatoetico@policlinico.ba.it). All examinations were performed according to local guidelines.

Statistical analysis

Variables were reported as means with standard deviations (SD), medians with interquartile ranges (IQR), or absolute numbers with percentages, as appropriate. The Shapiro-Wilk test was used to check for the distribution of data. Continuous variables were compared using a paired *t*-test or Mann-Whitney test, as appropriate. Categorical variables were compared using the Chi-square test. The repeated measures of the analysis of variance (ANOVA) with the Geisser-Greenhouse correction, or the non-parametric Friedman test, were used to assess changes in continuous variables during follow-up, as appropriate. The persistence of RTX therapy was assessed with Kaplan-Meier analysis. Statistical analysis was carried out using GraphPad Prism software (v. 9.5.1), with a p-value of <0.05 considered statistically significant.

Results

Patient characteristics

A total of 41 IIM patients [31 female (75.6%); age 55±15 years old; myositis subset: 15 (36.6%) DM, 15 (36.6%) ASS, 5 (12.2%) PM and 6 (14.6%) IMNM], were treated with RTX (2 g every 6 months, two 1g doses given 2 weeks apart). In our cohort, the median (IQR) disease duration was 6 (4-11) years, while the median (IQR) follow-up duration was 6 (4-9) years (Table 1). All subjects were previously treated with high-dose CCS and at least one csDMARD, according to local guidelines. At the time of RTX indication, all patients were on CCS, with a median (IQR) daily administered PDNeq dose of 15 mg (12.5-25 mg), while 30 patients (73.2%) continued csDMARDs therapy in association with RTX, most commonly methotrexate, mycophenolate mofetil, or azathioprine. The median (IQR) number of failed csDMARDs before RTX administration was 2 (2-3) in our cohort. The autoantibody

profile of IIM patients, including the presence of MSA or MAA, is described in *Supplementary Table 1*. In our cohort, 14 out of 15 DM patients (93.3%) presented skin manifestations such as periungual erythema, heliotrope rash, neck rash, shawl sign, or Gottron's papules, while 2 patients (13.3%) had calcinosis cutis. Cutaneous involvement was less frequently observed in other myositis subsets and was present in 9 out of 15 (60%) ASS patients (3 cases of mechanic's hands and/or hiker's feet, 3 cases skin ulcerations, 3 cases of periungual erythema and 2 cases of erythematous skin rash), one out of 6 (16.7%) IMNM patients with skin rash, and one out of 5 (20%) PM patients with periorbital erythema. Articular involvement was observed in 10 out of 15 (66.7%) ASS patients, 3 out of 5 (60%) PM patients, and 7 out of 15 (46.7%) DM patients, while no IMNM patients presented arthritis. Esophageal involvement was present in 10 out of 41 (24.4%) IIM patients, with dysphagia reported by 5 out of 15 (33.3%) DM patients, 2 out of 15 (13.3%) ASS patients, 2 out of 5 (40%) PM patients, and one out of 6 (16.7%) IMNM patients. Other comorbidities were present in 31 out of 41 IIM patients (75.6%) treated with RTX, most commonly systemic hypertension (13 cases, 31.7%), autoimmune thyroiditis (12 cases, 29.3%), and osteoporosis (11 cases, 26.8%). The most frequent reasons for RTX therapy indication were refractory myositis (61.0%), skin (56.1%), lung (53.6%), and joint (48.8%) involvements (*Supplementary Figure 1*).

Rituximab efficacy

Treatment with RTX was associated with a significant steroid-sparing effect. The median (IQR) daily dose of PDNeq decreased from 15 mg (12.5-25 mg) at baseline to 5 mg (5-5 mg) after 1 year of treatment ($p<0.001$ *vs.* baseline), and to 5 mg (0-5 mg) after 2 years ($p<0.001$ *vs.* baseline). Notably, a further significant reduction in the daily PDNeq dose at 2 years compared to the 1-year dose ($p<0.05$) was also observed (Figure 1). Overall, the mean clinical improvement, expressed as a mean (SD) TIS, was 45.4±18.1 at 1 year and 52.3±17.7 at 2 years of follow-up. The percentages of patients who achieved minor, moderate, major, or no response with a TIS score at 1 year and 2 years from the first RTX administration are shown in Figure 2. Of note, 90.6% and 90.9% of patients achieved at least a minor TIS at 1 year and 2 years of follow-up, respectively. Data regarding TIS in each subset of IIM is reported in Figure 3. ANOVA tests showed a significant improvement during follow-up of MMT-8 score ($p<0.0001$), CPK level ($p<0.01$), and FVC predicted level ($p<0.05$), while DLCO change over time was not statistically significant (Table 2). The 1-year RTX treatment persistence was 68.3% in our cohort, with 13 IIM patients (31.7%) discontinuing therapy. Primary inefficacy of RTX treatment was observed in 3 cases (7.3%). Additionally, one patient exhibited secondary inefficacy of RTX therapy, contribut-



Figure 1. Daily administered prednisone equivalent dose in patients with idiopathic inflammatory myopathies treated with rituximab at baseline, 1 year, and 2 years. *$p<0.0001$ *vs.* baseline; #$p<0.05$ vs. one year.

Table 1. Demographic and clinical characteristics of 41 patients with idiopathic inflammatory myopathies treated with rituximab.

Characteristics	
IIM subset:	
- DM	15 (36.6)
- ASS	15 (36.6)
- PM	5 (12.2)
- IMNM	6 (14.6)
Female, n. (%)	31 (75.6)
Age (years), mean ± SD	55.4±15.0
Disease duration (years), median (IQR)	6 (4-11)
Follow-up duration (years), median (IQR)	6 (4-9)
ANA positive (≥1/160), n (%)	34 (82.9)
MSA/MAA positive, n (%)	38 (92.7)
Muscle involvement, n (%)	25 (61.0)
Skin involvement, n (%)	25 (61.0)
Joint involvement, n (%)	20 (48.8)
Lung involvement, n (%)	22 (53.6)
csDMARD count at first RTX infusion, median and IQR (25-75)	2 (2-3)
Therapy with csDMARD at first RTX infusion, n (%)	30 (73.2)
Therapy with CCS at at first RTX infusion, n (%)	41 (100)

DM, dermatomyositis; ASS, anti-synthetase syndrome; PM, polymyositis; IMNM, immune-mediated necrotizing myopathy; IQR, interquartile range; SD, standard deviation; ANA, antinuclear antibody; MSA, myositis-specific antibody; MAA, myositis-associated antibody; RTX, rituximab; csDMARD, conventional synthetic disease-modifying anti-rheumatic drugs; CCS, corticosteroids; AE, adverse events.

ing to a total of 4 cases of ineffectiveness (9.8%). Kaplan Meier curves of RTX treatment persistence according to the reason for treatment discontinuation and the IIM subset are presented in Figure 4. No significant difference was observed according to the cause of RTX discontinuation (log-rank: 1.14; p=0.28). Analyzing RTX persistence according to IIM subsets, we observed a significantly lower drug persistence in the PM group compared to DM (log-rank: 5.84; p=0.02) and IMNM (log-rank: 6.27; p=0.01) subsets. Among cases of primary inefficacy, two patients were affected by ASS, one with joint involvement and another with both joint and muscle involvement, while one patient had IMNM with muscle involvement. As for secondary inefficacy, one patient with ASS experienced an ILD flare during follow-up. Finally, we assessed the persistence of RTX treatment in monotherapy and combination therapy with csDMARDs. No significant differences were observed between patients treated with RTX monotherapy or csDMARDs combination therapy, both for any cause of discontinuation (log-rank: 4.98; p=0.08) and when specifically assessing discontinuation due to ineffectiveness (log-rank: 1.77; p=0.41) or adverse events (log-rank: 3.23; p=0.21).

Rituximab safety

During the first year of treatment, ADRs were the most common cause of RTX discontinuation (4 skin reactions during RTX infusion, resolved after treatment interruption). Other reasons for RTX discontinuation within the first year included exitus (2 cases: one acute myocardial infarction and one acute respiratory insufficiency secondary to SARS-CoV-2 infection), positive cancer screening (2 cases: one pancreatic neuroendocrine tumor and one multiple myeloma), severe pulmonary infection (one case), and loss to follow-up (one case). During the entire follow-up period on full RTX dose, which had a median (IQR) duration of 22 (9-55) months, 2 additional patients died, totaling 4 deaths. However, the causes of death were known for only one patient, who died due to acute respiratory insufficiency secondary to SARS-CoV-2 infection. One more patient was lost to follow-up, bringing the total to two. Furthermore, there were 2 additional cases of skin reactions (6 in total) and one severe pulmonary infection that led to treatment discontinuation (2 cases in total). The most common reasons



Figure 2. Total improvement score (TIS) in patients with idiopathic inflammatory myopathies treated with rituximab at 1 year (TIS 12) and at 2 years (TIS 24). TIS is expressed as no improvement (0-19 points), minor (20-39 points), moderate (40-59 points), or major (60-100 points) improvement.



Figure 3. Total improvement score (TIS) of different subsets of patients with idiopathic inflammatory myopathies treated with rituximab at 1 year (TIS 12) and at 2 years (TIS 24). TIS is expressed as no improvement (0-19 points), minor (20-39 points), moderate (40-59 points) or major (60-100 points) improvement. ASS, anti-synthetase syndrome; DM, dermatomyositis; IMNM, immune-mediated necrotizing myopathy; PM, polymyositis.

Table 2. Laboratory and clinical data in patients with idiopathic inflammatory myopathies during rituximab treatment.

Characteristics	Baseline	1 year	2 years	p (ANOVA)
MMT-8 (0-150), median and IQR (25-75)	134 (108-144)	143 (139-149)***	148 (142-150)***,#	<0.0001
CPK U/L, median and IQR (25-75)	670 (160-3218)	110 (61-495) ***	129 (56-207)***	0.0013
DLCO (%) predicted, median and IQR (25-75)	53 (42-66)	59 (48-76)	63 (43-81)	0.4941
FVC (%) predicted, median and IQR (25-75)	71 (61-91)	83 (74-98)**	85 (74-95)*	0.0114

MMT, manual muscle test; CPK, creatine phosphokinase; DLCO, diffusion lung carbon monoxide; FVC, forced vital capacity; IQR, interquartile range; ANOVA, analysis of variance; p (ANOVA) <0.05; p-value *vs.* baseline (*<0.05, **<0.01, ***<0.001); p-value *vs.* 1-year (#<0.05, ##<0.01, ###<0.001).

for RTX discontinuation are reported in Table 3. All IIM patients undergoing RTX therapy were screened for tuberculosis infection and viral hepatitis according to local guidelines prior to the first RTX infusion. No cases of opportunistic infections, both bacterial and fungal, or viral infections such as CMV, EBV, or HBV reactivations were observed during follow-up. RTX treatment was associated with variations of serum Ig levels during the first 2 years of follow-up, with a significant decrease in IgA ($p<0.001$) and IgM ($p<0.0001$) levels, while the change in IgG levels was not statistically significant (Figure 5). No patients developed severe hypogammaglobulinemia (IgG<400 mg/dL) during the follow-up.

Discussion and Conclusions

In our study, we evaluated the effectiveness of RTX treatment in 41 IIM refractory to conventional therapies. We observed at least a minor improvement according to TIS in more than 90% of IIM patients with cutaneous, pulmonary, articular, or muscular manifestations refractory to multiple csDMARDs and high-dose CCS. The Myositis Response Criteria with TIS were used, as they have recently been shown to perform consistently across multiple studies, further confirming their validity in different IIM subsets (14). Treatment of refractory IIM represents a rheumatological challenge and an unmet clinical need nowadays. In fact, there are no standardized treatment guidelines for IIM, particularly due to the rarity of the disease and the lack of randomized controlled trials. Therefore, the therapeutic approach is mainly guided by expert opinion and case series (15). The first evidence of RTX use in myositis dates back to 2005, when Levine *et al*. demonstrated its

Table 3. Reasons for rituximab discontinuation.*

Reasons for discontinuation	Rituximab discontinuation, n. (%)
Adverse event	10 (24.3)
Ineffectiveness	4 (9.8)
Remission	3 (7.3)
Exitus	4 (9.8)
Lost to follow-up	2 (4.9)

*During follow-up, 23 out of 41 patients (56.1%) discontinued rituximab treatment for any reason, including persistent remission.



Figure 4. Kaplan-Meier curves of rituximab (RTX) treatment persistency with the reason for treatment discontinuation in different idiopathic inflammatory myopathy (IIM) subsets.



Figure 5. Peripheral blood level of immunoglobulin (Ig)A (**A**), IgG (**B**), and IgM (**C**) in idiopathic inflammatory myopathy patients treated with rituximab at baseline, 1 year, and 2 years. p-value *vs.* baseline (*<0.05, **<0.01, ***<0.001); p-value *vs.* 1-year ($^{\#}$<0.05, $^{\#\#}$<0.01, $^{\#\#\#}$<0.001).

efficacy in six patients with DM who were refractory to standard therapy (16). Since then, RTX has been progressively employed for the treatment of IIM, especially in life-threatening situations or when the symptoms do not improve or even get worse despite standard immunosuppressive therapies (17, 18). Despite the results of the RIM trial, most evidence supporting the efficacy of RTX in IIM has come from real-world studies (10, 19-21). Our study highlighted the effectiveness of RTX treatment in a cohort of IIM patients refractory to high-dose CCS and csDMARD therapy, but most notably, its good safety profile. The assessment of TIS during follow-up confirmed a relevant improvement in IIM patients. The effectiveness of RTX treatment for refractory muscle involvement was confirmed by a significant reduction in CPK level and an increase in MMT-8 score over time. Similarly, in IIM patients with refractory lung involvement, a significant improvement in FVC was observed. Other real-life studies of IIM patients confirm the positive effects of RTX treatment on lung function tests, muscle enzymes, and muscular weakness, while also permitting a reduction of CCS (22, 23). Notably, infections were considered the most relevant concern associated with RTX treatment (24, 25). In fact, a significant increase in severe infections was observed in a retrospective study involving 4479 patients following RTX treatment. However, it was also reported that many patients had not been screened or were not properly identified as having hypogammaglobulinemia before RTX administration (26). In our study, we assessed the safety profile of RTX treatment. The most common reason for treatment discontinuation was an adverse skin reaction during RTX infusion, with 6 cases noted during the observational period, but no severe or anaphylactic reactions. A total of 5 pulmonary infections requiring treatment interruption were observed, with 2 of these resulting in the death of the patient. Notably, COVID-19 infections accounted for both deaths. It is important to note that RTX can be a risk factor for a poor prognosis after a COVID-19 infection, highlighting the critical role of vaccinations in RTX-treated patients (27, 28). In our cohort, all patients were informed before starting RTX therapy about the importance of completing the vaccination schedule according to local recommendations, including SARS-CoV-2 vaccination given onsite to all IIM patients before starting RTX treatment, and advice to complete the vaccination schedule with at least the influenza, herpes zoster, and pneumococcal vaccines, ideally administered before the first RTX infusion or at least with the correct timing considering the 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases undergoing RTX treatment (29). The frequency and severity of hypogammaglobulinemia and potential infectious complications following RTX therapy were assessed in a large retrospective cohort of patients with systemic autoimmune diseases, including systemic vasculitis and SLE. After RTX treatment, IgM levels showed a significant decrease, but IgG levels remained stable. A high concomitant dose of CCS was identified as the most important risk factor for developing hypogammaglobulinemia (30). In our cohort, IgA and IgM levels decreased during the first 2 years of follow-up, while IgG levels remained stable. No IIM patients developed severe hypogammaglobulinemia. The fact that IgM is more significantly reduced during RTX therapy is not new; in fact, IgM is affected more than the other Ig by RTX (31). This might be attributed to the different impacts of RTX on distinct plasma-cell subsets. Specifically, short-lived plasma cells make a greater contribution to serum IgM than serum IgG, which fact might explain these results. Meanwhile, long-lived plasma cells, which lack CD20 and are therefore spared from RTX's actions, maintain good production of IgG. Finally, the disease itself may contribute to the different effects of RTX on the variation of Ig levels (27). Few studies have assessed RTX-induced hypogammaglobulinemia in IIM. A multicentric Italian study investigating the relevance of serum Ig levels in 30 myositis patients during RTX treatment suggested that hypogammaglobulinemia following RTX administration is uncommon in IIM and is not related to any clinical variables, including CCS dosage and previous treatments (32). The main limitations of our study included the small sample size, which hampered the ability to evaluate the influence of specific IIM biomarkers, such as positivity to MSA/MAA, or clinical biomarkers like disease duration, age, gender or concomitant therapies, as well as the short follow-up duration, which prevented us from estimating the long-term effects of RTX therapy. Notably, according to our data, DM and IMNM patients presented a significantly higher RTX persistence compared to PM patients, maybe secondary to the existence of "myositis chameleons", including metabolic myopathies, genetic myopathies, and neurological diseases, which mimic PM symptoms and represent a diagnostic and therapeutic challenge (33, 34). In conclusion, our results indicate that RTX is an effective and safe choice for refractory IIM patients, allowing for a significant steroid-sparing effect and often inducing disease remission. Nonetheless, particular attention must be given to the risk of infection, especially COVID-19.

References

1. Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Stine LC, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers 2021; 7: 86.
2. Rizzo C, La Barbera L, Barletta G, Camarda F, Donzella D, Romano G, et al. Characterising oesophageal motility disorders by high-resolution impedance manometry in dermatomyositis patients. Clin Exp Rheumatol 2024; 42: 344-50.
3. Basnayake C, Cash K, Blumbergs P, Limaye V. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. Clin Rheumatol 2015; 34: 371-7.
4. Nalotto L, Iaccarino L, Zen M, Gatto M, Borella W, Domeneghetti M, et al. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res 2013; 56: 362-70.
5. Mahler EAM, Blom M, Voermans NC, Van Engelen BGM, Van Riel PLCM, Vonk MC. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology 2011; 50: 2206-13.
6. Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology 2022; 61: 1760-8.
7. Glaubitz S, Zeng R, Schmidt J. New insights into the treatment of myositis. Ther Adv Musculoskelet Dis 2020; 12: 1759720X1988649.
8. Grazzini S, Rizzo C, Conticini E, D'Alessandro R, La Barbera L, D'Alessandro M, et al. The role of bDMARDs in idiopathic inflammatory myopathies: a systematic literature review. Autoimmun Rev 2023; 22: 103264.
9. Zhen C, Hou Y, Zhao B, Ma X, Dai T, Yan C. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Front Immunol 2022; 13: 1051609.

10. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo□phase trial. Arthritis Rheum 2013; 65: 314-24.
11. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76: 1955-64.
12. Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-mediated necrotizing myopathies working group. 224th ENMC international workshop:: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2018; 28: 87-99.
13. Boumaza X, Lafaurie M, Treiner E, Walter O, Pugnet G, Martin-Blonderl G, et al. Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases. Int Immunopharmacol 2023; 120: 110342.
14. Saygin D, Kim H, Douglas C, Erman B, Wilkerson J, McGrath JA, et al. Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles. Rheumatology 2023; 62: 3672-9.
15. Barsotti S, Lundberg IE. Current treatment for myositis. Curr Treatm Opt Rheum 2018; 4: 299-315.
16. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601-7.
17. McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol 2018; 14: 290-302.
18. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014; 66: 740-9.
19. De Souza FHC, Miossi R, De Moraes JCB, Bonfá E, Shinjo SK. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Adv Rheumatol 2018; 58: 31.
20. Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 2012; 106: 581-7.
21. Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology 2017; 56: 26-36.
22. Ahn GY, Suh CH, Kim YG, Park YB, Shim SC, Lee SH, et al. Efficacy and safety of rituximab in korean patients with refractory inflammatory myopathies. J Korean Med Sci 2020; 35: e335.
23. Xiong A, Yang G, Song Z, Xiong C, Liu D, Shuai Y, et al. Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series. Ther Adv Neurol Disord 2021; 14: 1756286421998918.
24. Unger L, Kampf S, Lüthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology 2014; 53: 1630-8.
25. Santos VA, Aragón CC, Posso-Osorio I, Naranjo-Escobar J, Milisenda JC, Obando MA, et al. Rituximab for inflammatory myopathies in a Colombian cohort. J Clin Rheumatol 2021; 27: S232-5.
26. Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 2018; 1: e184169.
27. Singh N, Madhira V, Hu C, Olex AL, Bergquist T Fitzgerlad KC, et al. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: a retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C). Semin Arthritis Rheum 2023; 58: 152149.
28. Conticini E, d'Alessandro M, Grazzini S, Fornaro M, Sabella D, Lopalco G, et al. Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study. Intern Emerg Med 2022; 17: 1921-8.
29. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79: 39-52.
30. Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 2014; 15: 178.

Contributions: FI, MF, SS, conceived and designed the study; FC, LC, GL, SS, collected data; MF, SS, performed the statistical analysis; FC, MF, SS, performed the literature review and wrote the report. All authors read and approved the final manuscript.

Conflict of interest: the authors declare no conflict of interest.

Ethics approval and consent to participate: the study was approved by the local Ethics Committee (INflammatoy MYositis Registry: study no. 6229, approval no. 84762,2020/11/06; comitatoetico@policlinico.ba.it).

Informed consent: all participants signed an informed consent prior to inclusion in the study.

Patient consent for publication: patient consent for publication is included in the informed consent of INMYRE registry.

Availability of data and materials: data and materials are available from the corresponding author upon request.

Funding: this research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Received: 9 November 2024.
Accepted: 17 April 2025.
Early access: 28 May 2025.

Reumatismo 2025; 77:1822
doi:10.4081/reumatismo.2025.1817